Background {#S5}
==========

Corticotropin-releasing hormone (CRH), a peptide that is synthesized and released from the hypothalamus, is the main central regulator in the hypothalamic-pituitary-adrenal (HPA) axis ^[@R1]^. During pregnancy, maternal CRH in the bloodstream is largely derived from placenta secretion and triggers secretion of maternal cortisol that activates more release of CRH from placenta ^[@R2]^. This feed-forward loop leads to an increase in maternal CRH ^[@R3]^ and a two- to four-fold higher maternal cortisol secretion in normal pregnancy ^[@R4]^. Placental enzymes only partially inactivate maternal cortisol, and a large amount of active cortisol are passed to the fetus ^[@R5]^. Fetal cortisol levels are positively correlated with maternal cortisol levels ^[@R6]^, and thus, maternal plasma CRH levels during pregnancy reflect the intensity of fetal cortisol exposure.

Fetal cortisol exposure leads to both beneficial and detrimental consequences: cortisol is necessary for fetal organ maturation (e.g., lung, kidney, heart) ^[@R7]^; however, in humans, excessively high levels of cortisol have been associated with preterm birth ^[@R6]^, small for gestational age ^[@R8]^, HPA axis dysfunction ^[@R9]^, and with obesity ^[@R10]^ and metabolic syndromes ^[@R11]^ later in life. Animal studies also showed adverse effects of excess cortisol that prenatal synthetic glucocorticoids treatments modify HPA axis function and increase the risk of obesity and diabetes in the offspring ^[@R12]--[@R15]^. These studies support the hypothesis that prenatal cortisol exposure -- regulated by maternal CRH -- contributes to the fetal growth and long-term development. Additionally, previous studies in our cohort have demonstrated that higher maternal CRH is associated with a higher risk of central adiposity and adiponectin levels in early childhood ^[@R16]^, but lower BMI in offspring ^[@R10]^.

DNA methylation is regarded as an important mechanism by which early life exposures may lead to long-term programming, sometimes leading to structural and functional changes that can persist later in life and have long-term effects ^[@R17],[@R18]^. Both human and animal studies found DNA methylation modifications at HPA-axis genes (e.g., *NR3C1, NR3C2, CRH, POMC, HSD11B2β*) and modified HPA-axis function in the offspring whose mother were treated with synthetic glucocorticoids during gestation^[@R19],[@R20]^. However, no prior study investigated the associations between maternal CRH and offspring DNA methylation in humans using an epigenome-wide approach.

We hypothesized that maternal CRH is associated with DNA methylation levels in cord blood, and some of the associations would last into mid-childhood. We investigated associations between maternal CRH levels and DNA methylation in cord blood cells in \>450,000 sites across the genome and evaluated whether these associations persist into mid-childhood.

Methods {#S6}
=======

Study population {#S7}
----------------

We recruited pregnant women into Project Viva during their first prenatal visit (initially 2128 mother-child pairs at median 9.9 gestation weeks) at eastern Massachusetts Atrius Harvard Vanguard Medical Associates practices, between 1999 and 2002. Details of this prospective pre-birth cohort have been described previously ^[@R21]^. We included 257 mother-child pairs in the cord blood analysis, and we included 239 mother-child pairs in mid-childhood (range: 6.7--10.3 years) DNA methylation analysis, according to availability of maternal CHR measurement and DNA methylation data that passed our sample quality control ([Figure S1](#SD1){ref-type="supplementary-material"}). We analyzed 134 mother-child pairs who had all data available at both time-points ([Figure S2](#SD1){ref-type="supplementary-material"}). All mothers provided written informed consent. The research was approved by the Institutional Review Board at Harvard Pilgrim Health Care.

Maternal corticotropin-releasing hormone (CRH) measurement {#S8}
----------------------------------------------------------

Collection of maternal blood samples, CRH measurement and data processing in this cohort has been previously described ^[@R22]^. Briefly, we assayed for CRH with an RIA assay kit (Peninsula Laboratories Inc., San Carlos, CA) following the manufacturer's instructions. To eliminate bias introduced by batch effect and gestational age at CRH test, we conducted a two-stage correction for the original CRH measurements. In the first stage, we adjusted CRH levels for batch effects (adjusted CRH = e^(ln(original\ CRH)\ +\ 0.48)^). In the second stage, we additionally adjusted CRH levels for gestational age at maternal blood drawn ^[@R10]^ ([Figure S3](#SD1){ref-type="supplementary-material"}). Henceforward, maternal CRH refers to the fully two-stage adjusted maternal CRH.

DNA methylation assessment {#S9}
--------------------------

Collection, processing, and storage of cord blood samples and children's peripheral blood in mid-childhood has been previously described ^[@R23]^. Trained laboratory staff extracted DNA from blood samples using commercially available PureGene Kits (Fisher, catalog \#: A407--4, A416--4; Qiagen, catalog \#: 158908, 158912, 158924) and conducted sodium bisulfite conversion on DNA using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA). We measured DNA methylation across the genome using the Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA) following standard manufacturer's protocols. To reduce the influence of batch effect and to ensure the balance of sex, samples were randomly allocated to assay chips, and chips were randomly assigned to plates.

Quality control {#S10}
---------------

The DNA methylation data processing is as previously described ^[@R23]^. We excluded 65 actual SNPs, 11648 probes on sex chromosomes, 2994 non-CpG probes, 8715 probes with poor detection (*P* \> 0.05) for more than 1% samples, 27951 cross-reactive probes ^[@R24]^ and 99224 SNP-containing probes ([Figure S4](#SD1){ref-type="supplementary-material"}). We included a total of 334980 out of 485577 CpGs in the analysis. For each CpG site, methylation level is represented by the average *β*-value = M/ (M+ U+ ε), where M and U represent the average fluorescence intensity corresponding to the methylated and unmethylated target CpG while ε usually equals 100. The average *β*-value, ranging between 0 and 1, is interpreted as the proportion CpG methylated at each site. *β*-scale DNA methylation levels were logit transformed to *M*-values (*M* = log~2~(*β*) -- log~2~(1 -- *β*)) for a distribution that was more appropriate for the analysis of DNA methylation. The batch effect was not associated with the first 30 principal components of DNA methylation variance in cord blood ([Figure S5](#SD1){ref-type="supplementary-material"}) and children's blood (plot not shown) after we performed the batch effect adjustment using ComBat approach, which indicated adequate removal of batch effects. We used ComBat to adjust for batch effect (details are described in the [Supplementary materials](#SD1){ref-type="supplementary-material"}).

Covariates {#S11}
----------

Using self-administered questionnaires and medical record data, we collected information of maternal age at enrollment, education level, race/ethnicity, smoking status, parity, pre-pregnancy body mass index (BMI), last menstrual period; and children's sex and birth weight. We estimated gestational age at delivery by subtracting the LMP date from the delivery date or by the ultrasound if the ultrasound estimation were available and differed from the LMP estimation by more than ten days. Based on U.S. national reference data ^[@R25]^, we calculated sex-specific birth weight-for-gestational age z-score using data on birth weight, gestational age, and child sex. We estimated the nucleated cell-type compositions (CD8 T-cells, CD4 T-cells, granulocytes, natural killer cells, B-cells, monocytes, and nucleated red blood cells) in the cord blood using a validated reference panel ^[@R26]^. We estimated the cell-type compositions (CD8 T-cells, CD4 T-cells, granulocytes, natural killer cells, B-cells and monocytes) in the children's peripheral blood in mid-childhood using adult leukocyte reference panel for blood samples as implemented in minfi ^[@R27]^.

Leptin and body composition measurements {#S12}
----------------------------------------

We measured leptin concentration in cord blood and plasma of children's blood in mid-childhood using a radioimmunoassay (Linco Research Inc, St Charles, MO), as described previously ^[@R28]^. We used log-transformed leptin concentration and removed outliers. We included 235 cord blood samples and 225 children's blood samples in our analyses. At mid-childhood, we measured children's height (cm), weight (kg), waist and hip circumferences (cm), subscapular (SS) and triceps (TR) skinfold thicknesses (mm), as described previously ^[@R29]^. We calculated age-sex-adjusted BMI z-score based on the U.S. national data ^[@R30]^, the sum of skinfold thicknesses (SS + TR) and waist-to-hip circumference ratios.

Statistical Analysis {#S13}
--------------------

We used mean \[standard deviations (SD)\], median (IQR) or percentages of covariates to describe characteristics of participants at birth and in mid-childhood. To test for individually differentially methylated CpG sites in relation to maternal CRH levels, we fit robust linear regression models for each CpG site on the *M*-value scale, adjusting for potential confounders including maternal age at enrollment, education, maternal race/ethnicity, maternal smoking status (never/former/current), pre-pregnancy BMI, parity, gestational age at delivery, child sex and cord blood cell-type estimation (CD8 T-cells, CD4 T-cells, natural killer cells, B-cells, monocytes, and nucleated red blood cells), using the *MASS* package in R. After inclusion of cell-type estimation and other potential confounders, the genomic inflation factor (λ) for the Epigenome-Wide Analysis was 1.03, indicating that results were unlikely driven by population stratification or cryptic relatedness ([Figure S6](#SD1){ref-type="supplementary-material"}). The statistical significance of the CpG-by-CpG analysis was evaluated using an FDR adjusted level (*q* \< 0.05). To ease biological interpretation, we presented the adjusted regression coefficient of maternal CRH on DNA methylation on the *β*-value scale. We also conducted a pathway analysis on the CpG sites passing the FDR using the 'gometh' function in 'missMethyl' package in R.

Subsequently, we performed a differentially methylated regional DNA methylation analysis using the *DMRcate* ^[@R31]^ package of R to examine the association between maternal CRH and differentially methylated regions (DMRs) in cord blood. We used a Gaussian kernel smoothing function to test statistics grouping significant CpG sites with bandwidth λ = 300 base pairs and scaling factor C = 2. Significance testing among DMRs was adjusted for multiple comparisons using a Stouffer adjusted *P* \< 0.05. We visualized the DMRs and their neighborhood regions using the *coMET* ^[@R32]^ in R.

Furthermore, we explored whether the associations of maternal CRH with differentially methylated CpG sites and regions in cord blood were persistent into mid-childhood using robust linear regression among our top candidate CpGs identified in our cord blood analyses. We regarded the mean methylation across all CpGs in the DMR as the regional methylation level, since the DNA methylation of CpGs in the DMR found in the present study were significantly correlated with each other. We adjusted robust linear regression models with maternal age at enrollment, education, maternal race/ethnicity, pre-pregnancy BMI, parity, child sex, cell-type estimations and the child's age at blood collection for DNA methylation test. We considered associations statistically significant for persistence in childhood when the *P* \< 0.05 for the one region we had found in cord blood DMR analyses, and we used FDR to correct for number of CpG sites found in the cord blood CpG-by-CpG analyses.

Additionally, we performed two sensitivity analyses to test for bias caused by prenatal steroid treatments and preterm birth. All analyses were carried out using the R software, version 3.4.1.

Code availability {#S14}
-----------------

Code is available upon request.

Results {#S15}
=======

Characteristics of participants {#S16}
-------------------------------

[Table 1](#T1){ref-type="table"} displays characteristics of mother-child pairs. In the participants included in the cord blood methylation analyses, the log~2~-transformed fully adjusted CRH levels ranged between 4.3 -- 9.7. Gestational age at blood draw for the CRH test ranged between 25 -- 34 gestational weeks. In the primary analysis of mother-child pairs with cord blood DNA methylation, a majority of mothers were white (73%), multiparous (55%), never smoked (68%), and college graduate (67%). Characteristics of participants included in analyses of DNA methylation measured in mid-childhood were similar to those of participants included in the cord blood analyses.

Genome-wide CpG-by-CpG analysis in cord blood {#S17}
---------------------------------------------

In robust linear regression models for individual CpG sites, we found 96 differentially methylated CpG sites (FDR \< 0.05) in cord blood relative to maternal CRH levels ([Table S1](#SD1){ref-type="supplementary-material"}). We showed the 7 CpG sites with the strongest associations that also reached Bonferroni adjusted significant level (*P* \< 1.49 × 10^−7^) in [Table 2](#T2){ref-type="table"}. The percent changes in cord blood DNA methylation per doubling in maternal CRH concentration (adjusted regression coefficient) ranged between 0.09% - 1.74% among the top 7 CpG sites and between 0.03% - 2.50% in absolute value among the overall 96 CpG sites. Among the 96 CpGs, cg12782180 (*P* = 1.32× 10^−08^), cg00840332 (*P* = 1.24 × 10^−07^), cg19594666 (*P* = 3.82 ×10^−07^) were annotated to leptin (*LEP*) gene (region within \<1500 base pairs from the transcription start site (TSS)), and had 1.74%, 0.81% and 1.86% increase in the DNA methylation levels in cord blood per doubling in maternal CRH concentration.

Among our top 7 differential CpG sites that reached Bonferroni adjusted significant level, we found 2 CpG sites annotated to *LEP* and the others were annotated to the following 5 genes: *ZNF428*, *LARGE*, *ARHGAP40*, *ADAMTS5*, *TGFA*. At all 7 Bonferroni significant CpG sites, greater maternal CRH was associated with higher methylation levels ([Figure 1](#F1){ref-type="fig"}). Similarly, methylation of the majority of 96 CpG sites (FDR \< 0.05) were positively correlated with maternal CRH level, such as cg07380705 (*CRHBP*), cg16527491 (*FOXA1*), cg22937891 (*TRIM36*), cg13641043 (*PLCD3*), cg01078147 (*SEMA6A*), cg07891473 (*ADAMTS9*), cg15558129 (*LYPLAL1*), and only eight show lower methylation levels associated with greater maternal CRH ([Table S1](#SD1){ref-type="supplementary-material"}).

The sensitivity analyses show that our results were robust: effect sizes of associations between maternal CRH and methylation at all 96 FDR significant CpG sites were very similar in effect size and statistical significance values to our primary analyses after excluding subjects who had prenatal steroid treatment or were born at gestational age less than 37 weeks.

We conducted pathway analysis on the 96 CpGs passing FDR in the CpG-by-CpG analysis, but did not observe any GO pathways passing 5% FDR threshold. The top 10 GO terms were shown in [Table S2](#SD1){ref-type="supplementary-material"}.

Differentially Methylated Regions {#S18}
---------------------------------

In regional DNA methylation analysis, we detected one differentially methylated region (DMR) in relation to maternal CRH exposure (Stouffer adjusted *P = 0.047*). This region consists of 4 consecutive CpG sites (cg00840332, cg19594666, cg26814075, cg13381984) annotated to *LEP* gene on chromosome 7 (genomic coordinate: chr7:127881269--127881344). This region includes two of the FDR-significant CpG sites (cg00840332, cg19594666) that we identified in CpG-by-CpG analysis. DNA methylation of each CpG site within the DMR of *LEP* was associated with 0.81% to 1.86% higher DNA methylation per doubling in maternal CRH concentration; the overall mean methylation of CpG sites across this region was 1.46% higher per doubling in maternal CRH level (*P* = 3.45 × 10^−7^) ([Table 3](#T3){ref-type="table"}). [Figure 2](#F2){ref-type="fig"} displays the *P*-value distribution of CpG sites in DMR of *LEP* gene and its neighborhood genomic region (upper panel), annotation of the region (middle panel) and the correlations among the CpG sites (lower panel). The methylation levels of the 4 CpG sites within the DMR of *LEP* were strongly and positively correlated with each other in cord blood cells (r = 0.65--0.90, *P* \< 2.2×10^−16^) and mid-childhood blood cells (r = 0.66--0.91, *P* \< 2.2×10^−16^); thus, we used the mean methylation of the 4 CpG sites in subsequent analyses to represent the methylation level of this region. [Figure S7](#SD1){ref-type="supplementary-material"} displays the DNA methylation of individual subjects for the 4 CpG sites in *LEP* region as well as the other 6 CpG sites passing the Bonferroni significant level in CpG-by-CpG analysis. In the sex-specific analysis ([Table S3](#SD1){ref-type="supplementary-material"}), the mean levels of DNA methylation at the *LEP* region in cord blood were similar in males and females; moreover, the associations between maternal CRH and *LEP* methylation were also significant in both females and males.

Persistence of associations in mid-childhood blood cell DNA methylation {#S19}
-----------------------------------------------------------------------

In the analysis on persistence, we first focus our attention on the *LEP* methylation because we believe the association between maternal CRH and *LEP* methylation is the most robust among all CpGs. Multiple significant CpGs were detected in the *LEP* promoter region; moreover, the CRH-associated *LEP* methylation was verified by regional analysis. We evaluated the persistence of the association between maternal CRH and the DMR of *LEP* gene in the children's blood samples in mid-childhood. The results were summarized in [Table 3](#T3){ref-type="table"}. The association between maternal CRH and DNA methylation at this DMR was attenuated at mid-childhood (mean methylation beta = 0.64% per doubling of maternal CRH; *P*=0.03), compared to cord blood associations (mean methylation beta= 1.46% per doubling of maternal CRH). In the sex-specific analysis ([Table S3](#SD1){ref-type="supplementary-material"}), mean levels of DNA methylation at the *LEP* region in mid-childhood were similar, and the associations between maternal CRH and *LEP* methylation were significant in females but not in males. We additionally explored the persistence of the association in mid-childhood for the 96 significant CpGs identified in cord blood. We found nominal associations between maternal CRH and mid-childhood blood methylation at 12 CpG sites (unadjusted *P* \< 0.05), yet only cg25936177 (*ACAN*) remained significant after accounting for multiple testing ([Table S4](#SD1){ref-type="supplementary-material"}).

Associations among maternal CRH, LEP methylation, leptin levels, birth weight and body composition in mid-childhood. {#S20}
--------------------------------------------------------------------------------------------------------------------

Higher maternal CRH was associated with lower leptin concentration in cord blood ([Table S5](#SD1){ref-type="supplementary-material"}), but we did not observe an association between *LEP* methylation and leptin concentration, both measured in cord blood. Also, lower leptin level in cord blood was correlated with lower birth weight ([Table S5](#SD1){ref-type="supplementary-material"}) as expected, but we did not found that maternal CRH or *LEP* methylation were associated with birth weight ([Table S5](#SD1){ref-type="supplementary-material"}). In mid-childhood, higher *LEP* methylation level in blood was associated with lower BMI z-score (β \[se\] = −3.11 \[1.32\], *P* = 0.02), log2-transformed skinfold thickness (β \[se\] = −1.92 \[0.72\], *P* = 0.01) and log2-transformed waist-hip ratio (β \[se\] = −0.18 \[0.10\], *P* = 0.07) ([Table S6](#SD1){ref-type="supplementary-material"}). The results indicated that one percent increase in *LEP* methylation was associated with 3.11 decrease in BMI z-score, 3.84 times smaller in skinfold thickness and 0.36 times smaller in waist-hip ratio. We did not detect a significant association between *LEP* methylation and leptin concentration in blood at mid-childhood (β \[se\] = −2.72 \[11.02\], *P* = 0.80).

Discussion {#S21}
==========

In this pre-birth prospective cohort study, we found that higher maternal CRH concentration in mid-late pregnancy was associated with higher DNA methylation of CpG sites of the *LEP* gene by both individual CpG-by-CpG and regional analyses, and that this association persisted into mid-childhood. We also observed that maternal CRH was associated with DNA methylation levels at many other individual CpG sites for a total of 96 CpG sites, yet few of these seemed to persist later in childhood.

To our knowledge, this is the first study reporting associations between maternal CRH and *LEP* DNA methylation both at birth and persisting in mid-childhood in humans. Although no prior study has described this association, one study demonstrated that maternal dexamethasone (a type of synthetic glucocorticoids) treatment induced the programming of liver steatosis in offspring rats through increased *LEP* DNA methylation and the subsequent decreased leptin levels ^[@R33]^, which is in line with our finding. Additional findings from the same team demonstrated that rats prenatally overexposed to glucocorticoids had lower leptin levels in fetal plasmas and placenta ^[@R34],[@R35]^. In a human study, mothers treated with betamethasone (a type of synthetic glucocorticoids) had offspring with lower leptin levels at birth ^[@R36]^. These studies support the association between high glucocorticoids exposure in pregnancy and lower circulating fetal leptin levels, as was the case of our observed positive correlation between maternal CRH and fetal *LEP* methylation and concordant with the known role of methylation down-regulating gene expression. The differentially methylated region of *LEP* found in our study was located in a CpG island, a CpG-rich region, within the proximal promoter region of *LEP* ^[@R37]^ containing many regulation elements of gene expression. Although the present study could not directly address the function of methylation in this region on gene expression due to lack of RNA data, prior studies have documented the negative regulatory effect of DNA methylation level at this region on the *LEP* expression in human preadipocytes ^[@R37]^, subcutaneous adipose tissue ^[@R38]^, and placenta tissues ^[@R39]^. However, it was worth noting that we measured the DNA methylation of the white blood cells (WBCs) and use it as a proxy for other tissues that secrete leptin. The DNA methylation status of WBCs cannot fully represent the *LEP* DNA methylation in other tissues, such as adipose tissue. Circulating leptin in blood is mainly released from fat tissues and to a lesser extend from other tissues ^[@R40]^. Therefore, the blood *LEP* methylation may not be the most relevant tissue predicting leptin levels in the circulation. It could be one of the reasons why the association between *LEP* methylation and circulating leptin were not significant at both two-time points in the present study. Another reason is the complex regulation of gene transcription and protein translation. Due to lack of RNA data, we do not know either the association between *LEP* methylation and *LEP* expression or the association between *LEP* expression and leptin translation. Apart from DNA methylation, many other processes are involved in the regulation of gene transcription (e.g., non-coding RNA and histone modifications ^[@R41]^) as well as protein translation (e.g., global and gene-specific regulations ^[@R42]^). Such factors may influence associations between *LEP* methylation and leptin levels that were not captured in our study.

Leptin regulates feeding and energy balance by affecting hypothalamic function to balance food intake and body fat mass ^[@R43]^. Additionally, leptin serves broader roles during pregnancy. Studies found that lower leptin levels in cord blood were significantly correlated with lower birth weight-for-gestational age z-score^[@R44][@R45]^, indicating the role of leptin in fetal growth. Moreover, the prior study of Project Viva found that lower cord blood leptin levels were associated with higher BMI at early childhood (3 years old) ^[@R46]^. The key roles of leptin in fetal growth and long-term development were also observed in *LEP* DNA methylation level. One study has found that the higher DNA methylation of *LEP* promoter in cord blood was associated with lower birth weight ^[@R47]^. However, we did not find significant association between *LEP* methylation and birth weight-for-gestational age z-score in the present study. This inconsistency may be attributed to our relatively small sample size or differences in the two populations including potential influence of genetic variation in *LEP* ^[@R47]^.

On average, the coefficients of prenatal CRH concentration on *LEP* DNA methylation is 1.46% in cord blood and 0.64% in children's blood, which are generally small effect sizes. Breton et al. have pointed out that small-magnitude effect sizes in DNA methylation are common, yet important in children's environmental health studies ^[@R48]^. Although no prior study documented the effect size of prenatal CRH on *LEP* methylation, several studies commonly found small but significant changes in *LEP* methylation (generally on the scale of 0.7%−2.3%) in relation to various exposures (e.g., prenatal PM~2.5~ exposure ^[@R49]^~,~ folic acid supplement ^[@R50]^, duration of breastfeeding ^[@R51]^). To support the functional importance of relatively small differences in the DNA methylation of *LEP*, we explored the association between *LEP* methylation and the anthropometric measurements in mid-childhood and found every 1% increase in methylation at *LEP*, there was a 3.11 decrease in BMI z-score, 3.84 times smaller in skinfold thickness and 0.36 times smaller in waist-hip ratio, which indicates that the small changes in methylation of *LEP* in relation to CRH can have strong effects on biological activity. Consistent with our findings, other studies also identified the inverse relationship between methylation at *LEP* promoter and children obesity ^[@R52]^ or indicator of obesity ^[@R53]^. An animal study also suggested that diet-induced obese rats had lower *LEP* DNA methylation in blood ^[@R54]^.

Among other CpG sites that reached Bonferroni significant level, we found cg13523649 (mean (SD) methylation level of 0.29 (0.04)) annotated to *ARHGAP40* gene that encodes a Rho GTPase activating protein 40 involved in GTPase activator activity. Studies on *ARHGAP40* gene are sparse, but the Rho GTPase activating protein family was found to be important in neuronal development ^[@R55]^. Interestingly, corticotropin-releasing factors modulate the brain neuronal morphology through Rho GTPases regulators in the process of stress response ^[@R56]^, which suggested a close relationship between Rho GTPase activating protein and corticotropin-releasing factors. These studies supported the association between maternal CRH and *ARHGAP40* methylation present in our study.

Among other FDR-significant CpG sites where CRH was associated with cord blood DNA methylation, cg07380705 is annotated to Corticotropin-Releasing Hormone Binding Protein (*CRHBP*), which encodes a protein with important modulatory roles relative to CRH activity through binding with CRH and limiting the bioavailability of CRH ^[@R57]^. CRHBP is widely detected in human tissues including the placenta. Circulating plasma CRHBP in humans prevents inappropriate pituitary-adrenal stimulation caused by elevated plasma CRH during pregnancy ^[@R57]^. CRHBP is positively regulated by CRH concentration ^[@R58]^ as well as stress factors that are known to affect HPA axis activity ^[@R59]^. On epigenetics level, one study observed that maternal war trauma-related stress was associated with increased DNA methylation of one *CRHBP* CpG site (cg17448335) in placenta ^[@R60]^. This CpG site locates only 121bp upstream of cg07380705 that was found associated with maternal CRH levels in our present study. Moreover, the two CpG sites are all located within the same CpG island. Interestingly, CRHBP is not only involved in regulation of HPA axis activity through binding with CRH but also participates in mediating energy balance and metabolism through counteracting the thermogenic and anorectic actions of CRH ^[@R57]^. Our finding of *CRHBP* methylation changes supported the effect of maternal CRH on the energy metabolism of offspring. We also detected three CpG sites (cg16527491 *FOXA1* ^[@R61]^, cg22937891 *TRIM36* ^[@R62]^, cg13641043 *PLCD3*^[@R63]^) annotated to the genes that are associated with blood pressure, and three CpG sites (cg01078147 *SEMA6A* ^[@R64]^, cg07891473 *ADAMTS9*^[@R65]^, cg15558129 *LYPLAL1*^[@R65]^) annotated to the genes that are linked to body mass index and waist-hip ratio. *PLCD3* (Phospholipase C Delta 3) encodes a member of the phospholipase C family, which are important in vascular smooth muscle signaling. One genome-wide association study (GWAS) has demonstrated that the common variants of *PLCD3* were associated with systolic blood pressure ^[@R63]^. *LYPLAL1* (Lysophospholipase Like 1) encodes a protein involved in the regulation of hydrolase activity and lysophospholipase activity. Multiple GWAS observed the common variants of *LYPLAL1* associated with neonatal anthropometric measures ^[@R66]^, adult waist-hip ratio ^[@R65]^ and adiponectin levels ^[@R67]^. However, among the 96 CpGs, only one (cg25936177, *ACAN*) has persistent association with maternal CRH in mid-childhood. The lack of significant associations in mid-childhood could be explained by a few factors: first, some CpGs detected in cord blood with low variability may be false positive findings, according to Logue et al.'s study ^[@R68]^; second, the effect of maternal CRH on fetal DNA methylation could be modified by many known and unknown factors between birth and mid-childhood. The effect on early life methylation may lead to changes at molecular, cellular, or tissue levels that persist through life, while the actual associations between prenatal exposure and methylation levels are not detectable because of additional modulations of methylation.

Among our strengths, this study prospectively evaluated the persistence of DNA methylation variabilities in childhood. In addition, this study is based on a well-characterized prospective cohort study, which enabled us to evaluate a large set of potential confounders. Furthermore, the regional analysis confirmed our CpG-by-CpG analyses. Lastly, we had the opportunity to analyze the potential influence of *LEP* DNA methylation on circulating leptin levels and anthropometric characteristics in the same dataset.

However, our study also had some important limitations. First, we only measured CRH level at one point in pregnancy, which may not comprehensively reflect maternal CRH level over the whole pregnancy and neglects the diurnal rhythm of CRH. In addition, we do not have data on gene expression measurements to assess the functionality of DNA methylation at the *LEP* locus; moreover, we do not have data on DNA methylation of tissues that predominantly secrete leptin, mainly adipose tissue. Many of our significant findings were at CpG sites with low (\< 5%) or high (\>95%) mean DNA methylation levels across all samples, which often indicated low variabilities with an increased risk of false positive ^[@R68]^. Moreover, we only pursued analyses of associations between maternal CRH and DNA methylation in mid-childhood blood for the CpG sites we had identified at birth; we acknowledge that other signals may emerge later in life but are not detectable in cord blood.

Conclusion {#S22}
==========

This study adds to the growing body of evidence showing that glucocorticoid exposure in pregnancy is associated with children's health programming. Variations in DNA methylation levels of *LEP* promoter observed at birth might provide a potential explanation for the short- and long-term health effects of prenatal glucocorticoid exposure in offspring.
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![Scatterplots for the associations between differentially methylated CpGs (Bonferroni p \< 1.49 ×10^−7^) and maternal corticotropin-releasing hormone level (log~2~-transformed CRH corrected for technician and gestational age at CRH test) during pregnancy. The red regression line was fitted with simple linear regression. The blue was non-parametric regression line with locally weighted smoothing. The Pearson correlation coefficient of each CpG site resulted from partial correlation analysis adjusted for maternal age, education, maternal race/ethnicity, gestational age, pre-pregnancy BMI, parity, child sex and cell-type estimations.](nihms-1508199-f0001){#F1}

![Regional plot of the *LEP* gene DMR and its neighborhood area. The upper panel shows the *P* values of CpGs methylation in the epigenome-wide association with maternal CRH. The middle panel provides the annotation tracks, including ENSEMBL Genes, CpG islands tracked from UCSC, DNase cluster tracked from UCSC, SNPs tracked from UCSC. The lower panel shows the correlation of methylation among the CpGs in this selected region. The CpG sites in the differentially methylated region (DMR) of *LEP* gene was marked.](nihms-1508199-f0002){#F2}

###### 

Characteristics of mothers and children included in analyses at birth and in mid-childhood.

  Characteristics                                                                              Cord blood       Middle childhood
  -------------------------------------------------------------------------------------------- ---------------- ------------------
  **Mothers**                                                                                                   
  Maternal age at enrollment, years: Mean (SD)                                                 32.1 (5.3)       32.2 (5.3)
  Pre-pregnancy BMI, kg/m^2^: Mean (SD)                                                        24.4 (4.9)       24.7 (5.3)
  Mothers' race/ethnicity: N (%)                                                                                
      . White                                                                                  189 (73)         162 (68)
      . Black                                                                                  29 (11)          41 (17)
      . Hispanic                                                                               21 (8)           15 (6)
      . Other                                                                                  18 (7)           21 (9)
  Nulliparous: N (%)                                                                           115 (45)         106 (44)
  \>= College graduate: N (%)                                                                  173 (67)         166 (70)
  Smoking status: N (%)                                                                                         
      . Never                                                                                  176 (68)         169 (71)
      . During pregnancy                                                                       26 (10)          24 (10)
      . Former                                                                                 55 (21)          46 (19)
  Log~2~-transformed CRH corrected for technician and gestational age at CRH test, Mean (SD)   7.1 (0.8)        7.1 (0.9)
  Gestational age at CRH test, weeks: Mean (SD)                                                27.9 (1.3)       27.9 (1.7)
  **Children**                                                                                                  
  Gestational age at delivery, weeks: Mean (SD)                                                39.7 (1.3)       39.6 (1.4)
  Birth weight, g: Mean (SD)                                                                   3559.1 (514.4)   3554.3 (528.4)
  Birth weight (z-score)^[a](#TFN2){ref-type="table-fn"}^: Mean (SD)                           0.3 (1.0)        0.3 (1.0)
  Age at blood samples collection                                                                               
      . At birth (gestational age in weeks)                                                    39.7 (1.3)       \-
      . In middle childhood (6.7 to 10.3 years)                                                \-               7.9 (0.8)
  Female: N (%)                                                                                126 (49)         115 (48)
  Children's race/ethnicity: N (%)                                                                              
      . White                                                                                  178 (69)         153 (64)
      . Black                                                                                  34 (13)          45 (19)
      . Hispanic                                                                               14 (5)           11 (5)
      . Other                                                                                  31 (12)          30 (13)
  BMI z-score: Mean (SD), n = 236                                                              \-               0.40 (1.3)
  Skinfold thickness (mm): Median (IQR), n = 236                                               \-               16.4 (8.7)
  Waist-hip ratio: Median (IQR), n = 237                                                       \-               0.9 (0.1)

BMI, body mass index. CRH, corticotropin-releasing hormone.

Birth weight adjusted for gestational age and child sex using U.S. national reference

###### 

CpG sites with differential DNA methylation at birth (257 cord blood samples) in relation to maternal CRH level during pregnancy (reaching *P* \< 1.49 × 10^−7^).

  CpGs         Mean (SD)     β-Coefficient (SE)^[a](#TFN4){ref-type="table-fn"}^ %   *P* ^[b](#TFN5){ref-type="table-fn"}^   FDR ^[b](#TFN5){ref-type="table-fn"}^   Position ^[c](#TFN6){ref-type="table-fn"}^   Island ^[c](#TFN6){ref-type="table-fn"}^   Gene ^[c](#TFN6){ref-type="table-fn"}^   Region ^[c](#TFN6){ref-type="table-fn"}^
  ------------ ------------- ------------------------------------------------------- --------------------------------------- --------------------------------------- -------------------------------------------- ------------------------------------------ ---------------------------------------- ------------------------------------------
  cg26180126   0.01 (0.00)   0.09 (0.02)                                             1.43 × 10^−7^                           0.01                                    chr2: 70779764                               N_Shore                                    *TGFA*                                   Body
  cg12782180   0.28 (0.06)   1.74 (0.31)                                             1.32 × 10^−8^                           1.47 × 10^−3^                           chr7: 127880932                              Island                                     *LEP*                                    TSS1500
  cg00840332   0.05 (0.03)   0.81 (0.17)                                             1.24 × 10^−7^                           0.01                                    chr7: 127881269                              Island                                     *LEP*                                    TSS200
  cg18656583   0.02 (0.00)   0.14 (0.02)                                             1.37 × 10^−10^                          4.57 × 10^−5^                           chr19: 44124056                              Island                                     *ZNF428*                                 TSS200
  cg13523649   0.29 (0.04)   1.42 (0.26)                                             8.79 × 10^−8^                           0.01                                    chr20: 37230741                              Island                                     *ARHGAP40*                               Body
  cg13601496   0.02 (0.00)   0.15 (0.03)                                             1.20 × 10^−7^                           0.01                                    chr21: 28339487                              Island                                     *ADAMTS5*                                TSS200
  cg21028171   0.03 (0.01)   0.19 (0.03)                                             8.73 × 10^−10^                          1.46 × 10^−4^                           chr22: 34316977                              Island                                     *LARGE*                                  TSS1500

Chr, chromosome; UTR, untranslated region; TSS, transcription start site. SD, standard deviation. SE, standard error of coefficient.

The coefficients are estimated according to the robust linear regression on beta value scale, adjusted for maternal age at enrollment, maternal education level, maternal race, maternal smoking status, pre-pregnant BMI, parity, gestational age at delivery, child sex, and the estimated proportions of CD8 T-cell, CD4 T-cell, natural killer cells, B-cells, monocytes, and red blood cells in cord blood. The coefficient of each CpG site represents the percent change in cord blood DNA methylation in relation to per doubling increased maternal CRH level during pregnancy.

The *P* values and FDRs are estimated according to the robust linear regression on M-value scale, adjusted for the same covariates with the model on beta value scale.

The annotation information are according to the R package of "IlluminaHumanMethylation450kanno.ilmn12.hg19".

###### 

DNA methylation of CpG sites in the differentially methylated region of *LEP* (chr7:127880932--127881440) at birth (cord blood) and at mid--childhood (blood) in relation to maternal CRH level during pregnancy.

  CpG                                       Position      Region          Island        At birth (cord blood) (N = 257)   Mid-childhood (N = 239)                 
  ----------------------------------------- ------------- --------------- ------------- --------------------------------- ------------------------- ------------- ------
      Mean DNA methylation of this region   1.46 (0.29)   3.45 × 10^−7^   0.64 (0.30)   0.03                                                                      
  cg00840332                                127881269     TSS200          island        0.81 (0.17)                       1.24 × 10^−7^             0.55 (0.24)   0.02
  cg19594666                                127881280     TSS200          island        1.86 (0.38)                       3.82 × 10^−7^             0.70 (0.43)   0.10
  cg26814075                                127881298     TSS200          island        1.51 (0.38)                       7.29 × 10^−5^             0.66 (0.35)   0.06
  cg13381984                                127881344     1stExon         island        1.48 (0.38)                       1.28 × 10^−4^             0.71 (0.34)   0.03

TSS, transcription start site. SD, standard deviation. SE, standard error of coefficient.

The coefficients are estimated according to the robust linear regression on beta value scale, adjusted for maternal age at enrollment, maternal education level, maternal race, maternal smoking status, pre-pregnant BMI, parity, gestational age at delivery, child sex, and the estimated proportions of CD8 T-cell, CD4 T-cell, natural killer cells, B-cells, monocytes, and red blood cells (cord blood only), age of children in years at the time of the blood draw for DNA methylation test (childhood only). The coefficient of each CpG site represents the percent change in DNA methylation in relation to per doubling increased maternal CRH level during pregnancy.

The *P* values are estimated according to the robust linear regression on M-value scale, adjusted for the same covariates with the model on beta value scale.
